GlassScriptPhysician profile
Douglas K Pleskow
NPI 1891777660
$117,993.25
in general payments reported to CMS, 2019-2025
18 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $5,815 · 2021: $8,021 · 2022: $20K · 2023: $19K · 2024: $23K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,951 · Travel and Lodging: $2,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,216.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,951.27 |
| Travel and Lodging | $2,774.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38,226.70 | 2019-2025 | General - Therapies, Exalt Model D, Spyglass |
| Olympus Corporation of The Americas | $28,261.18 | 2019-2025 | Evis Exera III Colonovideoscope, Evis Exera III Duodenovideoscope, Evis Exera Lll Colonovideoscope |
| Olympus Corporation | $22,528.75 | 2019-2025 | |
| Fujifilm Healthcare Americas Corporation | $11,513.41 | 2019-2021 | |
| Medtronic, INC. | $5,796.81 | 2021-2025 | Sharkcore, Endoflip |
| Fujifilm New Development USA, INC. | $3,600.00 | 2019-2020 | |
| Covidien LP | $3,232.14 | 2019 | |
| Olympus Medical Systems Corporation | $3,104.71 | 2024 | |
| Gyrus Acmi, INC. | $1,537.50 | 2023 | |
| Olympus America INC. | $69.02 | 2019-2021 | |
| Gilead Sciences, INC. | $29.96 | 2025 | |
| Pentax of America, INC. | $27.21 | 2022 | |
| Pfizer INC. | $24.16 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.64 | 2019 | |
| Abbvie INC. | $20.06 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Pleskow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.